Lexicon Pharmaceuticals | LXRX - Nettoeinkommen





Nettoeinkommen Veränderung Datum
Abbott USD 1.78B 132M 2025-12
Acadia Pharmaceuticals USD 273.57M 201.79M 2025-12
Agios Pharmaceuticals USD -108.04M 4.61M 2025-12
Akebia Therapeutics USD -12.24M 12.78M 2025-12
Alnylam Pharmaceuticals USD 186.42M 64.66M 2025-12
AstraZeneca USD 2.33B 207M 2025-12
BioMarin Pharmaceutical USD -46.57M 15.83M 2025-12
Coherus Biosciences USD -37.64M 2.11M 2025-12
Eli Lilly USD 6.64B 1.05B 2025-12
Esperion Therapeutics USD 61.83M 93.16M 2025-12
Halozyme Therapeutics USD -141.59M 316.82M 2025-12
Illumina USD 334M 184M 2025-12
Insmed USD -328.48M 41.54M 2025-12
Ironwood Pharmaceuticals USD 3.19M 457K 2024-12
J&J USD 5.12B 36M 2025-12
Lexicon Pharmaceuticals USD -15.53M 2.76M 2025-12
MacroGenics USD -14.16M 30.98M 2025-12
MannKind USD -15.95M 23.93M 2025-12
Merck USD 2.96B 2.82B 2025-12
Moderna USD -200M 625M 2025-09
Novartis USD 2.41B 1.52B 2025-12
PTC Therapeutics USD -134.96M 150.86M 2025-12
Puma Biotechnology USD 20.32M 24.85M 2024-09
Sarepta Therapeutics USD -412.23M 232.28M 2025-12
Thermo Fisher Scientific USD 1.96B 348M 2025-12
Ultragenyx Pharmaceutical USD -129M 51.41M 2025-12
United Therapeutics USD 364.3M 25.6M 2025-12
Vanda Pharmaceuticals USD -18.9M 13.58M 2024-12